These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26311072)

  • 21. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
    Minion LE; Tewari KS
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab-induced hypertension: pathogenesis and management.
    Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
    BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
    Cartwright TH
    Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
    Pineda E; Salud A; Vila-Navarro E; Safont MJ; Llorente B; Aparicio J; Vera R; Escudero P; Casado E; Bosch C; Bohn U; Pérez-Carrión R; Carmona A; Ayuso JR; Ripollés T; Bouzas R; Gironella M; García-Albéniz X; Feliu J; Maurel J
    Tumour Biol; 2017 Jun; 39(6):1010428317705509. PubMed ID: 28621236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteonecrosis of the mandible associated with bevacizumab therapy.
    Santos-Silva AR; Belizário Rosa GA; Castro Júnior Gd; Dias RB; Prado Ribeiro AC; Brandão TB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Jun; 115(6):e32-6. PubMed ID: 23567260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab.
    Mahajan D; Miller C; Hirose K; McCullough A; Yerian L
    J Hepatol; 2008 Nov; 49(5):867-70. PubMed ID: 18814928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
    Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2011; 59(6):410-3. PubMed ID: 22313910
    [No Abstract]   [Full Text] [Related]  

  • 31. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
    Fakih M
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing patients with metastatic colorectal cancer on bevacizumab.
    Lemmens L; Claes V; Uzzell M
    Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization.
    Bohndiek SE; Kettunen MI; Hu DE; Brindle KM
    Cancer Res; 2012 Feb; 72(4):854-64. PubMed ID: 22223844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The horizon of antiangiogenic therapy for colorectal cancer.
    Olszewski AJ; Grossbard ML; Kozuch PS
    Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
    Azzariti A; Porcelli L; Brunetti O; Del Re M; Longo V; Nardulli P; Signorile M; Xu JM; Calabrese A; Quatrale AE; Maiello E; Lorusso V; Silvestris N
    World J Gastroenterol; 2016 Jul; 22(27):6287-95. PubMed ID: 27468218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
    Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV
    Oncology; 2009; 76(3):209-11. PubMed ID: 19212145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
    Yoshida M; Goto M; Kii T; Nishitani H; Kawabe S; Kuwakado S; Asaishi K; Miyamoto T; Higuchi K
    Digestion; 2013; 87(1):59-64. PubMed ID: 23343971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
    Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
    Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.